Baptist Heart & Vascular Institute Research
June 2025
The BHVI research goal is to enhance patient care by offering access to the newest treatment alternatives.
The research department is conducting a study to evaluate if an investigational drug (Factor XIa) is non-inferior to apixaban for the composite of stroke and non-CNS embolism in patients with atrial fibrillation. In early studies, no major bleeding events or cardiovascular changes were noted.
Research is also involved in two studies to demonstrate the efficacy of an investigational drug on reducing fasting triglyceride levels for patients with elevated triglyceride levels. One study is looking for participants with triglyceride levels ≥ 500 mg/dL and the other with triglyceride levels ≥ 150 and ≤ 499 mg/dL. The investigational drug targets APOC3. A potential risk is worsening blood sugar levels in patients with pre-existing diabetes based on a temporary increase in HbA1c.
A heart failure trial will start in the spring of 2025. The purpose of the study is to investigate the effect of an investigational drug combined with dapagliflozin compared to dapagliflozin alone on the risk of cardiovascular death and heart failure events for patients with symptomatic heart failure. The investigational drug is believed to reduce the risk of complications from heart failure and impaired kidney failure by another mechanism than dapagliflozin.
If you would like additional information about our research program, please call 448.227.6690.
Our research goal is to enhance patient care by offering access to the newest treatment alternatives.
See our past research